Poland – Medicinal products for the blood and blood-forming organs – HUMANIZED monoclonal ANTIBODY that is an inhibitor of the tissue factor-dependent coagulation pathway - concizumab with successive deliveries to centers for the treatment of hemophilia and related bleeding disorders and patients' homes (which is considered the patient's place of residence or permanent stay); reference number: ZZP.ZP.411.160.2026
TenderZenith matches this tender's eligibility criteria against your company profile to calculate a deterministic qualification score and identify potential disqualifiers.
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Description & Project Overview
The subject of the order includes the supply to Direct Recipients (Treatment Centers for Hemophilia and Related Hemorrhagic Disorders) of a humanized monoclonal antibody that is an inhibitor of the tissue factor-dependent coagulation pathway - concizumab, together with administration kits - hereinafter referred to as the "medicinal product", in order to ensure the treatment of patients with hemophilia B complicated with an inhibitor, as part of the implementation of the health policy program of the minister responsible for health entitled "National Program for the Treatment of Patients with Hemophilia and Related Hemorrhagic Disorders for 2024-2028", hereinafter referred to as